1. Home
  2. IGC vs ZBAI Comparison

IGC vs ZBAI Comparison

Compare IGC & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGC
  • ZBAI
  • Stock Information
  • Founded
  • IGC 2005
  • ZBAI 2015
  • Country
  • IGC United States
  • ZBAI United States
  • Employees
  • IGC N/A
  • ZBAI N/A
  • Industry
  • IGC Biotechnology: Pharmaceutical Preparations
  • ZBAI Professional Services
  • Sector
  • IGC Health Care
  • ZBAI Consumer Discretionary
  • Exchange
  • IGC Nasdaq
  • ZBAI Nasdaq
  • Market Cap
  • IGC 20.2M
  • ZBAI 17.3M
  • IPO Year
  • IGC N/A
  • ZBAI N/A
  • Fundamental
  • Price
  • IGC $0.31
  • ZBAI $0.33
  • Analyst Decision
  • IGC Strong Buy
  • ZBAI
  • Analyst Count
  • IGC 2
  • ZBAI 0
  • Target Price
  • IGC $3.88
  • ZBAI N/A
  • AVG Volume (30 Days)
  • IGC 230.9K
  • ZBAI 2.4M
  • Earning Date
  • IGC 08-07-2025
  • ZBAI 06-06-2025
  • Dividend Yield
  • IGC N/A
  • ZBAI N/A
  • EPS Growth
  • IGC N/A
  • ZBAI N/A
  • EPS
  • IGC N/A
  • ZBAI N/A
  • Revenue
  • IGC $1,236,000.00
  • ZBAI $720,000.00
  • Revenue This Year
  • IGC N/A
  • ZBAI N/A
  • Revenue Next Year
  • IGC $16.45
  • ZBAI N/A
  • P/E Ratio
  • IGC N/A
  • ZBAI N/A
  • Revenue Growth
  • IGC 1.65
  • ZBAI 44.00
  • 52 Week Low
  • IGC $0.25
  • ZBAI $0.31
  • 52 Week High
  • IGC $0.55
  • ZBAI $2.50
  • Technical
  • Relative Strength Index (RSI)
  • IGC 49.31
  • ZBAI N/A
  • Support Level
  • IGC $0.30
  • ZBAI N/A
  • Resistance Level
  • IGC $0.32
  • ZBAI N/A
  • Average True Range (ATR)
  • IGC 0.02
  • ZBAI 0.00
  • MACD
  • IGC -0.00
  • ZBAI 0.00
  • Stochastic Oscillator
  • IGC 20.00
  • ZBAI 0.00

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

Share on Social Networks: